SEC Form 4 · accession 0001209191-16-094215
PORTOLA PHARMACEUTICALS INC · PTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Lis
Officer — Chief Executive Officer · Director
Period of report
Jan 27, 2016
Accepted (ET)
Jan 29, 2016 · 5:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001269021
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 27, 2016 | A | 28,125 | $0.00 | A | 28,125 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $33.49 | Jan 27, 2016 | A | 112,500 | A | — | Jan 27, 2026 | Common Stock | 112,500 | 112,500 | D |
| Performance Stock UnitF3 | — | Jan 27, 2016 | A | 28,125 | A | — | Jan 27, 2020 | Common Stock | 28,125 | 28,125 | D |
Explanation of responses
- F1Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSU vests annually over three years commencing on March 1, 2016, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date.
- F2The option shares shall vest as follows: 1/48th of the shares subject to the option shall vest each month after January 1, 2016, subject to the Reporting Person's Continuous Service as of each such date.
- F3Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of Issuer's Common Stock. The PSUs vest as follow: 50% of the PSUs will become vested upon achievement of the Issuer's gross product sales target for Andexanet alfa, and up to 50% of the remaining PSUs may vest subject to the timing of approval of Betrixaban by the United States Food and Drug Administration.